Upcoming event

The gender-specific urinary and bladder tissue microbiome in therapy-naive bladder cancer patients

November 2019

Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer

JAMA Oncol. , April 2018

Fibroblast growth factor receptor 3 alterations and response to PD-1/PD-L1 blockade in patients with metastatic urothelial cancer

European Urology, Volume 76, Issue 5, November 2019, Pages 599-603

Multicenter validation of histopathologic tumor regression grade after neoadjuvant chemotherapy in muscle-invasive bladder carcinoma

The American Journal of Surgical Pathology, September 2019

Reduction of pain during flexible cystoscopy: a systematic review and meta-analysis

Journal of Urology, June 2019

Programmed death-1 or programmed death ligand-1 blockade in patients with platinum-resistant metastatic urothelial cancer: A systematic review and meta-analysis

European Urology, June 2019

Long‐term Functional and Oncologic Outcomes of nerve sparing and prostate capsule sparing cystectomy: a single center experience

BJU International, June 2019

Sex-specific differences in the quality of treatment of muscle-invasive bladder cancer do not explain the overall survival discrepancy

European Urology Focus, June 2019

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer

May 2019

Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182

May 2019

Molecular subtyping of clinically localized urothelial carcinoma reveals lower rates of pathological upstaging at radical cystectomy among luminal tumors

European Urology, April 2019

FGFR3 mutations and their relation to FGFR3 expression and clinical outcome in a large radical cystectomy cohort: Implications for anti-FGFR3 bladder cancer treatment?

March 2019

Next